Join Us and Your ColleaguesWorld ExpertsYour FriendsIn-Person or Online
Please join us November 4-6, 2021 in Philadelphia, PA or LIVE online for the SH-EAHP 2021 Workshop.
The goal of this workshop is to examine cases of transformation and transdifferentiation (lineage switch) in lymphoid malignancies in respect to their morphology and genetic findings as well as address diagnostic challenges including changes in morphology caused by novel treatments with a variety of targeted therapies including inhibitor drugs. Cases of lymphoma trans-differentiation and cases which do not meet WHO criteria for transformation and yet show significant phenotypic and/or genetic changes will be particularly welcomed.
The areas of particular interest will be to address specific genetic abnormalities contributing to the transformation or transdifferentiation including rearrangements of MYC and BCL6 genes and mutations of TP53 gene and highlight novel insights into molecular mechanisms contributing to tumor progression and lineage switch in lymphoid malignancies. Another focus of this workshop will be elucidating the impact of targeted therapies as potential contributors to transformation and transdifferentiation and redefining the role of the hematopathologists in the light of the new genetic and therapeutic advances.
Extensive molecular characterization (the whole exome sequencing combined with whole genome RNA expression analysis with interpretation of these data) will be offered free of charge to the workshop participants for inclusion in their presentations.
Lectures on the current status on the diagnosis and management of patients who experienced disease progression will also be presented at this Workshop
Ahmet Dogan, MD, PhD
Mariusz A. Wasik, MD
Amy Duffield, MD
James R. Cook, MD, PhD
Magdalena Czader, MD, PhD
Reza Nejati, MD
Wenbin Xiao, MD, PhD
Don't miss out!
A unique feature of this workshop will be addition of in-depth molecular analysis of selected cases to reveal potential pathogenic genomic aberrations and/or identify novel therapeutic targets.